Johnson & Johnson Poised to Join $100 Billion Sales Club, Defying Industry Headwinds
The healthcare behemoth's robust 2025 results and 2026 guidance signal a landmark year ahead, as it navigates patent expirations and pricing pressures while maintaining its coveted dividend king status.